ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.04
0.60%
US Tech 100
17,446.00
2.17%
S&P 500
5,127.79
1.26%
US Dollar vs CAD
1.36685
0.00%
Bitcoin
63,764.47
-0.20%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) News

ACRV Acrivon Therapeutics Inc

9.59
1.13 (13.36%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Acrivon Therapeutics Inc ACRV NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
1.13 13.36% 9.59 23:00:01
Open Price Low Price High Price Close Price Previous Close
8.51 8.31 10.29 9.59 8.46
more quote information »

Recent News

Date Time Source Heading
4/24/202415:01GLOBEAcrivon Therapeutics Reports Initial Positive Clinical Data..
4/16/202419:01GLOBEAcrivon Therapeutics to Host Corporate R&D Event..
4/10/202407:00GLOBEAcrivon Therapeutics Presents Data at AACR Annual Meeting..
4/09/202406:00GLOBEAcrivon Therapeutics Announces $130 Million Private..
3/28/202407:00GLOBEAcrivon Therapeutics Reports Fourth Quarter and Full Year..
3/06/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/06/202415:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
3/05/202415:30GLOBEAcrivon Therapeutics to Present Data at AACR Annual Meeting..
3/04/202407:15EDGAR2Form 8-K - Current report
3/04/202407:00GLOBEAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA,..
2/27/202407:00GLOBEAcrivon Therapeutics to Participate in a Panel Discussion at..
2/16/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/13/202414:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/08/202407:27EDGAR2Form 8-K - Current report
2/08/202407:00GLOBEAcrivon Therapeutics Appoints Seasoned Industry Executive..
2/06/202407:00GLOBEAcrivon Therapeutics to Present at the Oppenheimer 34th..
1/19/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/12/202415:00GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
1/08/202406:28EDGAR2Form 8-K - Current report
1/04/202407:00GLOBEAcrivon Therapeutics to Present at the 42nd Annual J.P...
12/17/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
12/08/202315:21EDGAR2Form 8-K - Current report
12/01/202315:35EDGAR2Form S-3 - Registration statement under Securities Act of..
11/28/202307:58DJNAcrivon Therapeutics Gets FDA's Breakthrough Designation for..
11/28/202307:00GLOBEAcrivon Therapeutics Announces FDA has Granted Breakthrough..
11/21/202307:00GLOBEAcrivon Therapeutics Announces Inducement Grant Under Nasdaq..
11/16/202318:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/16/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/09/202308:12EDGAR2Form 8-K - Current report
11/09/202307:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202307:01GLOBEAcrivon Therapeutics Reports Third Quarter 2023 Financial..
10/19/202318:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/16/202307:00GLOBEAcrivon Therapeutics Presents Data Demonstrating..
9/28/202318:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/28/202318:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
9/28/202315:05GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
9/19/202315:32GLOBEAcrivon Therapeutics to Highlight its ACR-368 OncoSignature..
9/05/202316:23EDGAR2Form 8-K - Current report
9/05/202315:05GLOBEAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1..
8/30/202307:00GLOBEAcrivon Therapeutics to Participate in Two Investor..
8/23/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

NASDAQ
ACRV
Acrivon Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved